Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Releases active CNP that binds natriuretic peptide receptor B (NPR-B/guanylyl cyclase B) in growth-plate chondrocytes, increasing intracellular cGMP and attenuating FGFR3-mediated signalling that suppresses endochondral bone growth.
Indications / reported uses
To increase linear growth in paediatric patients aged 2 years and older with achondroplasia and open epiphyses under the US FDA YUVIWEL indication (approved 27 February 2026); accelerated approval is based on improved annualised growth velocity
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Navepegritide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Navepegritide Permitted Daily Exposure (PDE) report (the Navepegritide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Navepegritide Occupational Exposure Limit (OEL) report (the Navepegritide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.